UBS Group Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND)

UBS Group started coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note issued to investors on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $196.00 target price on the biotechnology company’s stock.

Several other research analysts also recently issued reports on ASND. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Oppenheimer dropped their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. JPMorgan Chase & Co. lowered their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, Stifel Nicolaus lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $192.07.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $137.29 on Tuesday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The business has a fifty day moving average price of $132.06 and a two-hundred day moving average price of $133.58. The stock has a market capitalization of $8.33 billion, a PE ratio of -16.99 and a beta of 0.65.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC increased its position in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares in the last quarter. Profund Advisors LLC grew its stake in Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 85 shares during the period. Rhumbline Advisers increased its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth $30,000. Finally, GAMMA Investing LLC grew its position in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.